Targeting CD30L in B-cell non-Hodgkin lymphoma: novel peptide conjugates and their therapeutic potential
In summary, our findings underscore the potential of CD30L as a novel target for B-NHL treatment and demonstrate the promise of CD30L-targeted peptides in advancing precision medicine for B-NHL, paving the way for future clinical developments.
Authors
- Chaowen Shi (ORCID: https://orcid.org/0000-0002-3498-1906)
- Yanbei Tu (ORCID: https://orcid.org/0000-0002-0877-0427)
- Zhigang Tu (ORCID: https://orcid.org/0000-0001-9844-3245)
- Yafei Zhang (ORCID: https://orcid.org/0000-0003-3035-0565)
- Hanqing Liu (ORCID: https://orcid.org/0000-0001-7984-6305)
- Trần Thị Lan (ORCID: https://orcid.org/0000-0001-9910-1415)
- Yufeng Gao (ORCID: https://orcid.org/0000-0001-5506-144X)
- Zhiquan Liang
Institutions
- Jiangsu University (CN)
Publication Details
- Journal
- Molecular Cancer
- Published
- 2025-07-05
- DOI
- https://doi.org/10.1186/s12943-025-02393-9
- Citations
- 1
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- National Natural Science Foundation of China
- Government of Jiangsu Province
- Natural Science Foundation of Jiangsu Province